吉非替尼维持治疗晚期非小细胞肺癌的疗效

目的：评价晚期非小细胞肺癌（NSCLC）一线化疗后，疗效非进展患者给予吉非替尼维持治疗的疗效与安全性。方法将46例一线化疗后疗效非进展NSCLC患者按治疗方法不同分为2组：对照组18例采用最佳支持疗法（BSC）治疗，观察组28例在BSC治疗基础上给予吉非替尼维持治疗。比较2组的临床疗效与不良反应发生情况。结果观察组总有效率（RR）28.6%，疾病控制率（DCR）82.1%；对照组RR 5.6%， DCR 62.1%，2组比较差异均无统计学意义（P＞0.05）。观察组无进展生存期（PFS）显著高于对照组（中位PFS 11.07个月比3.77个月，P=0.006）；观察组总生存期（OS）30.07个月，对照组18.17个月，2组比较差异无统计学意义（P=0.24）。观察组常见不良反应有皮疹（15/28,53.6%）、转氨酶升高（7/28,25.0%）、腹泻（6/28,21.4%）。结论吉非替尼维持治疗晚期非小细胞肺癌安全有效，能延长患者生存期。

Gefitinib Maintenance Therapy for Advanced Non-Small-Cell Lung Cancer

Objective To evaluate the efficacy and safety of gefitinib maintenance therapy in advanced non-small-cell lung cancer（NSCLC）patients without disease progression after first-line che-motherapy.Methods Forty-six NSCLC patients without disease progression after first-line chemo-therapy were given the best support therapy （control group, n=18） or in combination with gefitinib maintenance therapy （observation group, n=28）. Clinical efficacy and adverse reactions were compared between the two groups. Results The overall response rate was 28.6% in observation group and 5.6%in control group. The disease control rate was 82.1% in observation group and 62.1% in control group. There were no significant differences in the overall response rate and disease control rate between the two groups （P〉0.05）.Compared with control group, the median progression-free survival was significantly prolonged in observation group （11.07 months vs 3.77 months, P=0.006）. However, the difference in the overall survival was not significant between observation group and control group （30.07 months vs 18.17 months, P=0.24）. In observation group, the common adverse events included rash （15/28, 53.6%） , ALT increased （7/28, 25.0%） and diarrhea （6/28, 21.4%）. Conclusion Gefitinib maintenance therapy is effective and safe and can prolong survival in patients with NSCLC.